High DOCK1 expression identifies a distinct prognostic subgroup of pediatric acute myeloid leukemia: Results of the Japanese Pediatric Leukemia/Lymphoma Study Group AML-05 trial.

Masahiro YoshitomiShin-Ichi TsujimotoJunji IkedaTomoko KawaiKentaro OhkiYusuke HaraGenki YamatoReo TanoshimaMasanori YoshidaAkira ShimadaKeizo HoribeSouichi AdachiTakashi TagaAkio TawaYasuhide HayashiShuichi ItoNorio Shiba

Published in: Pediatric blood & cancer (2024)

Our results indicate that a DOCK1 inhibitor might reinforce the effects of cytarabine and other anti-cancer agents in patients with AML with high DOCK1 expression.

Keyphrases

acute myeloid leukemia
poor prognosis
allogeneic hematopoietic stem cell transplantation
phase iii
clinical trial
binding protein
long non coding rna
genome wide
randomized controlled trial
diffuse large b cell lymphoma
low dose
high dose